IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Open accessThe DOI matches its Crossref record; 40 of the 50 references it cites were found in a registry or an index.
Abstract
The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets.However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo.We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12.This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes.Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells.Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity.These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, increase in IL-12 levels might enhance the efficacy of immunotherapy by increasing the production of IFN-ɤ to stimulate the development and enhance the cytotoxicity of activated NK cells (100) and T cells and to accelerate the differentiation of CD4+ Th0 cells toward the Th1 phenotype, thus improving antibody-dependent cellular cytotoxicity (101).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [100]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A. A., Doherty, P. C., Grosveld, G. C., et al. (1996) · Nature · doi:10.1038/382171a0 · Cited by 1,180
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Self-citationPegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Research works printed but not linked: 10
- Sarup, J.C., et al. 1991. Characterization of an anti-p185HER2 mono- clonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:72-82.
- Baselga, J., and Albanell, J. 2001. Mechanisms of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:S35-S41. · doi:10.1023/a:1011163824080
- Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mech- anism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
- Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neu- expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
- Fleming, G.F., et al. 1999. A phase I CALGB trial of recombinant human anti-HER2 monoclonal antibody plus low-dose interleukin2 in solid tumors. Proc. Am. Soc. Clin. Oncol. 18:184a. (Abstr. 710)
- Weiner, L.M., et al. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:4586-4593.
- Penichet, M.L., Dela Cruz, J.S., Shin, S.U., and Morrison, S.L. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies. 10:43-49. · doi:10.3233/hab-2000-10107
- Peng, L.S., Penichet, M.L., and Morrison, S.L. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250-258. · doi:10.4049/jimmunol.163.1.250
- Cavallo, F., et al. 1999. Immune events associated with the cure of estab- lished tumors and spontaneous metastases by local and systemic inter- leukin-12. Cancer Res. 59:414-421.
- Parihar, R. et al. 2001. A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. Proc. Am. Soc. Clin. Oncol. 20:258a. (Abstr. 1031)
Cited by
Items 201–212 of 212
Poly(L-glutamic acid) based composites for improved dual immune checkpoint blockade therapyPreprint
Xue, F., Yao, H., Sun, J., Ren, X., Hu, J., Shen, N., & Tang, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3940308/v1
Kim, S. M., & Shin, K. (2024) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2024.53.7.669
Hohmeier, T. (2007) · Dokumentenrepositorium der RUB (Ruhr University Bochum)
Understanding the tumor microenvironment in glioblastoma for the development of focused therapies
Nieland, L. (2025) · Leiden Repository (Leiden University)
Barra, C. D. (2024) · Maynooth University ePrints and eTheses Archive (Maynooth University)
Griswold, R. Q. (2024) · eScholarship (California Digital Library)
Caractérisation des rôles de CLCF1 dans la biologie de l’IL-12
Laplante, V. (2025) · doi:10.71781/32656
Amidpour, G. (2025) · TSpace (University of Toronto)
Mikhailova, V., Marko, O. B., Mkrtchyan, E. R., & Sokolov, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083599
Gallina, A. M. (2026) · Nova Science Publishers (Nova Science Publishers, Inc.)
Choi, D., Kim, H.-J., Kim, H., & Chung, D. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12764-0
Altaie, A. M., Venkatachalam, T., Samaranayake, L. P., Soliman, S. S. M., & Hamoudi, R. (2021) · doi:10.3389/fimmu.2021.707267.s001
Metadata
- Authors
- Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University (US)
- Corresponding author
- Carson, William E.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 983-992
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4237052860
- Cited by
- 23
- References
- 40
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Funders
- Ohio State University
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- IL-12, natural killer cells, monoclonal antibodies, antitumor immunity, FcγRIII, IL-12 receptor, monocytes, antibody-dependent cellular cytotoxicity, anti-idiotypic antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.